Does Rallies show live market data for JAZZ?

Rallies combines live market context with ticker research for JAZZ, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

JAZZ (Jazz Pharmaceuticals, Inc.) Stock Analysis

Jazz Pharmaceuticals, Inc. (JAZZ) is a publicly traded Healthcare sector company. As of May 21, 2026, JAZZ trades at $239.96 with a market cap of $14.40B and a P/E ratio of 26.45. JAZZ moved +0.70% today. Year to date, JAZZ is +37.05%; over the trailing twelve months it is +115.29%. Its 52-week range spans $95.49 to $242.18. Analyst consensus is strong buy with an average price target of $241.43. Rallies surfaces JAZZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest JAZZ stock research?

Jazz Pharmaceuticals, Inc. (JAZZ) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. JAZZ moved +0.70% today. Analyst consensus is strong buy.

JAZZ Key Metrics

Key financial metrics for JAZZ
Metric	Value
Price	$239.96
Market Cap	$14.40B
P/E Ratio	26.45
EPS	$9.06
Dividend Yield	0.00%
52-Week High	$242.18
52-Week Low	$95.49
Volume	5
Avg Volume	0
Revenue (TTM)	$4.07B
Net Income	$560.12M
Gross Margin	0.00%

Latest JAZZ News

Jazz Pharmaceuticals jumps on Q1 revenue surge, EPS beat, and reaffirmed 2026 outlook — May 6, 2026
Jazz Pharmaceuticals Reports 19% Revenue Growth to $1.1B, Zanidatamab Granted Priority Review — May 5, 2026
Jazz Pharmaceuticals rises as ASCO 2026 Ziihera data looms, analyst optimism builds — Apr 27, 2026
Jazz Pharmaceuticals Gets FDA Priority Review, August 25 PDUFA for Ziihera in HER2+ GEA — Apr 27, 2026
Jazz Pharmaceuticals Sets May 5 Q1 Report, Showcases ASCO Data for Ziihera and Zepzelca — Apr 21, 2026

Recent JAZZ Insider Trades

COZADD BRUCE C sold 6.00K (~$1.22M) on May 1, 2026.
COZADD BRUCE C sold 3.68K (~$700.78K) on Apr 1, 2026.
COZADD BRUCE C sold 2.29K (~$437.63K) on Apr 1, 2026.

JAZZ Analyst Consensus

15 analysts cover JAZZ: 0 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $241.43.

Common questions about JAZZ

What can I research for JAZZ on Rallies?: Jazz Pharmaceuticals, Inc. (JAZZ) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. JAZZ moved +0.70% today. Analyst consensus is strong buy.
Does Rallies show live market data for JAZZ?: Rallies combines live market context with ticker research for JAZZ, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.